Plasma cell myeloma
RecruitingStudy on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination
Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination
- Disease:Plasma cell myeloma
- Substances:BortezomibDaratumumab+8
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Emn Trial Office S.r.l. Impresa Sociale











